$PLX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Protalix BioTherapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Protalix BioTherapeutics, Inc.. Get notifications about new insider transactions in Protalix BioTherapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 13 2020 | PLX | Protalix BioTherap ... | Rubin Eyal | Sr. VP and CFO | Grant | A | 0.00 | 246,146 | 0 | 246,146 | 0 to 246.1 K |
Aug 13 2020 | PLX | Protalix BioTherap ... | Bashan Dror | President and CEO | Grant | A | 0.00 | 447,927 | 0 | 447,927 | 0 to 447.9 K |
Aug 13 2020 | PLX | Protalix BioTherap ... | Naos Yaron | Sr. VP, Operations | Option Exercise | A | 3.59 | 122,656 | 440,335 | 122,656 | |
Jul 08 2020 | PLX | Protalix BioTherap ... | Hayon Yael | VP, Research & Deve ... | Option Exercise | A | 3.73 | 129,771 | 484,046 | 129,771 | |
Jun 08 2020 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Chief Developm ... | Option Exercise | A | 3.59 | 196,995 | 707,212 | 196,995 | |
Apr 13 2020 | PLX | Protalix BioTherap ... | Schwartz Aharon | Director | Buy | P | 2.43 | 64,000 | 155,264 | 64,000 | 0 to 64 K |
Feb 05 2020 | PLX | Protalix BioTherap ... | Bronfeld Zeev | Director | Option Exercise | A | 3.70 | 240,000 | 888,000 | 240,000 | |
Jan 22 2020 | PLX | Protalix BioTherap ... | Granot David | Director | Option Exercise | A | 3.55 | 40,000 | 142,000 | 40,000 | |
Jan 22 2020 | PLX | Protalix BioTherap ... | Bar-Shalev Amos | Director | Option Exercise | A | 3.55 | 40,000 | 142,000 | 40,000 | |
Jan 22 2020 | PLX | Protalix BioTherap ... | Schwartz Aharon | Director | Option Exercise | A | 3.55 | 40,000 | 142,000 | 40,000 | |
Jan 22 2020 | PLX | Protalix BioTherap ... | Boudes Pol F | Director | Option Exercise | A | 3.55 | 40,000 | 142,000 | 40,000 | |
Jan 22 2020 | PLX | Protalix BioTherap ... | Melincoff Gwen A | Director | Option Exercise | A | 3.55 | 40,000 | 142,000 | 40,000 | |
Sep 24 2019 | PLX | Protalix BioTherap ... | Rubin Eyal | Sr. VP & CFO | Option Exercise | A | 0.20 | 800,000 | 160,000 | 800,000 | |
Jul 02 2019 | PLX | Protalix BioTherap ... | Bashan Dror | President & CEO | Option Exercise | A | 0.47 | 1,600,000 | 750,400 | 1,600,000 | |
Sep 14 2018 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | A | 0.56 | 700,000 | 392,000 | 700,000 | |
Sep 14 2018 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Option Exercise | A | 0.56 | 700,000 | 392,000 | 700,000 | |
Sep 14 2018 | PLX | Protalix BioTherap ... | Naos Yaron | Sr. VP, Operations | Option Exercise | A | 0.56 | 600,000 | 336,000 | 600,000 | |
Sep 14 2018 | PLX | Protalix BioTherap ... | Manor Moshe | President & CEO | Option Exercise | A | 0.56 | 1,300,000 | 728,000 | 1,300,000 | |
Sep 14 2018 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Option Exercise | A | 0.56 | 700,000 | 392,000 | 700,000 | |
May 16 2017 | PLX | Protalix BioTherap ... | Manor Moshe | President & CEO | Buy | P | 0.81 | 50,000 | 40,500 | 50,000 | 0 to 50 K |
Dec 06 2016 | PLX | Protalix BioTherap ... | Camber Capital Management LLC | 10% Owner | Sell | S | 0.32 | 2,500,000 | 792,000 | 10,775,000 | 13.3 M to 10.8 M (-18.83 %) |
Sep 16 2016 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Option Exercise | M | 0.00 | 122,162 | 122 | 0 | |
Sep 16 2016 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Buy | M | 0.00 | 122,162 | 122 | 585,916 | 463.8 K to 585.9 K (+26.34 %) |
Dec 15 2015 | PLX | Protalix BioTherap ... | Maimon Yossi | Vice President & CF ... | Buy | P | 0.78 | 10,000 | 7,800 | 10,000 | 0 to 10 K |
May 07 2015 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | A | 1.72 | 250,000 | 430,000 | 250,000 | |
May 07 2015 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Option Exercise | A | 1.72 | 275,000 | 473,000 | 275,000 | |
May 07 2015 | PLX | Protalix BioTherap ... | Palash Tzvi | Chief Operating Off ... | Option Exercise | A | 1.72 | 125,000 | 215,000 | 125,000 | |
May 07 2015 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Option Exercise | A | 1.72 | 250,000 | 430,000 | 250,000 | |
Oct 06 2014 | PLX | Protalix BioTherap ... | Bronfeld Zeev | Director | Buy | J | 0.00 | 324,372 | 0 | 2,162,481 | 1.8 M to 2.2 M (+17.65 %) |
Oct 06 2014 | PLX | Protalix BioTherap ... | Bronfeld Zeev | Director | Sell | J | 0.00 | 1,509,948 | 0 | 0 | 1.5 M to 0 (-100.00 %) |
Nov 03 2014 | PLX | Protalix BioTherap ... | Manor Moshe | President & CEO | Option Exercise | A | 2.37 | 900,000 | 2,133,000 | 900,000 | |
Sep 18 2014 | PLX | Protalix BioTherap ... | Bronfeld Zeev | Director | Buy | J | 0.00 | 1,838,109 | 0 | 1,838,109 | 0 to 1.8 M |
Sep 18 2014 | PLX | Protalix BioTherap ... | Bronfeld Zeev | Director | Sell | J | 0.00 | 8,556,371 | 0 | 1,509,948 | 10.1 M to 1.5 M (-85.00 %) |
Sep 18 2014 | PLX | Protalix BioTherap ... | Bio-Cell Ltd | 10% Owner | Sell | J | 0.00 | 8,556,371 | 0 | 1,509,948 | 10.1 M to 1.5 M (-85.00 %) |
Aug 15 2014 | PLX | Protalix BioTherap ... | Bronfeld Zeev | Director | Sell | S | 2.47 | 4,400,000 | 10,868,000 | 10,066,319 | 14.5 M to 10.1 M (-30.42 %) |
Aug 15 2014 | PLX | Protalix BioTherap ... | Bio-Cell Ltd | 10% Owner | Sell | S | 2.47 | 4,400,000 | 10,868,000 | 10,066,319 | 14.5 M to 10.1 M (-30.42 %) |
Jul 24 2014 | PLX | Protalix BioTherap ... | Yanai Shlomo | Director | Option Exercise | A | 3.37 | 150,000 | 505,500 | 150,000 | |
Aug 16 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.07 | 2,330 | 11,813 | 4,915,383 | 4.9 M to 4.9 M (-0.05 %) |
Aug 16 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.08 | 5,000 | 25,400 | 4,917,713 | 4.9 M to 4.9 M (-0.10 %) |
Aug 16 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.07 | 5,000 | 25,350 | 4,922,713 | 4.9 M to 4.9 M (-0.10 %) |
Aug 16 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.05 | 100,000 | 505,000 | 4,927,713 | 5 M to 4.9 M (-1.99 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.71 | 5,000 | 28,550 | 5,037,711 | 5 M to 5 M (-0.10 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.72 | 10,000 | 57,200 | 5,042,713 | 5.1 M to 5 M (-0.20 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.75 | 3,000 | 17,250 | 5,052,713 | 5.1 M to 5.1 M (-0.06 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.79 | 300 | 1,737 | 5,055,713 | 5.1 M to 5.1 M (-0.01 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.95 | 1,898 | 11,293 | 5,056,013 | 5.1 M to 5.1 M (-0.04 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.92 | 2,500 | 14,800 | 5,057,911 | 5.1 M to 5.1 M (-0.05 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.91 | 2,500 | 14,775 | 5,060,411 | 5.1 M to 5.1 M (-0.05 %) |
Mar 12 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.82 | 10,000 | 58,200 | 5,062,911 | 5.1 M to 5.1 M (-0.20 %) |
Mar 14 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.70 | 10,000 | 57,000 | 5,027,713 | 5 M to 5 M (-0.20 %) |
Mar 08 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.73 | 3,435 | 19,683 | 5,072,911 | 5.1 M to 5.1 M (-0.07 %) |
Mar 08 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.71 | 5,000 | 28,550 | 5,076,346 | 5.1 M to 5.1 M (-0.10 %) |
Mar 08 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.71 | 700 | 3,997 | 5,081,346 | 5.1 M to 5.1 M (-0.01 %) |
Mar 08 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.69 | 2,000 | 11,380 | 5,082,046 | 5.1 M to 5.1 M (-0.04 %) |
Mar 08 2013 | PLX | Protalix BioTherap ... | Akirov Alfred | Director | Sell | S | 5.68 | 2,000 | 11,360 | 5,084,046 | 5.1 M to 5.1 M (-0.04 %) |
Jul 18 2012 | PLX | Protalix BioTherap ... | Maimon Yossi | Vice President & CF ... | Grant | A | 0.00 | 185,000 | 0 | 185,000 | 0 to 185 K |
Jul 18 2012 | PLX | Protalix BioTherap ... | Lauterbach Sandra Leigh | VP, Sales & Commerc ... | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
Jul 18 2012 | PLX | Protalix BioTherap ... | Palash Tzvi | Chief Operating Off ... | Grant | A | 0.00 | 102,000 | 0 | 102,000 | 0 to 102 K |
Jul 18 2012 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Grant | A | 0.00 | 210,000 | 0 | 210,000 | 0 to 210 K |
Jul 18 2012 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Grant | A | 0.00 | 185,000 | 0 | 185,000 | 0 to 185 K |
Jul 18 2012 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Grant | A | 0.00 | 418,000 | 0 | 418,000 | 0 to 418 K |
May 04 2012 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.13 | 300,000 | 2,139,000 | 463,754 | 763.8 K to 463.8 K (-39.28 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | M | 2.65 | 50,000 | 132,500 | 0 | |
May 04 2012 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | M | 0.97 | 75,964 | 73,837 | 0 | |
May 04 2012 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Sell | S | 7.13 | 125,964 | 898,123 | 0 | 126 K to 0 (-100.00 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Buy | M | 2.65 | 50,000 | 132,500 | 125,964 | 76 K to 126 K (+65.82 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Buy | M | 0.97 | 75,964 | 73,837 | 75,964 | 0 to 76 K |
May 04 2012 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Option Exercise | M | 0.97 | 123,733 | 120,268 | 853,563 | |
May 04 2012 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Option Exercise | M | 0.12 | 326,267 | 39,152 | 0 | |
May 04 2012 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Sell | S | 7.13 | 450,000 | 3,208,500 | 0 | 450 K to 0 (-100.00 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Buy | M | 0.97 | 123,733 | 120,268 | 450,000 | 326.3 K to 450 K (+37.92 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Buy | M | 0.12 | 326,267 | 39,152 | 326,267 | 0 to 326.3 K |
May 04 2012 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Option Exercise | M | 2.65 | 50,000 | 132,500 | 0 | |
May 04 2012 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Option Exercise | M | 0.97 | 116,848 | 113,576 | 0 | |
May 04 2012 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Sell | S | 7.13 | 166,848 | 1,189,626 | 0 | 166.8 K to 0 (-100.00 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Buy | M | 2.65 | 50,000 | 132,500 | 166,848 | 116.8 K to 166.8 K (+42.79 %) |
May 04 2012 | PLX | Protalix BioTherap ... | Almon Einat Brill | SVP, Product Develo ... | Buy | M | 0.97 | 116,848 | 113,576 | 116,848 | 0 to 116.8 K |
Oct 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | M | 0.97 | 77,769 | 75,591 | 75,964 | |
Oct 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Payment of Exercise | F | 9.73 | 7,769 | 75,592 | 0 | 7.8 K to 0 (-100.00 %) |
Oct 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Buy | M | 0.97 | 77,769 | 75,591 | 0 | -77,769 to 0 (-100.00 %) |
Oct 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Sell | S | 9.67 | 70,000 | 676,900 | 0 | 70 K to 0 (-100.00 %) |
Oct 06 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Option Exercise | M | 0.97 | 70,000 | 68,040 | 116,848 | |
Oct 06 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Buy | M | 0.97 | 70,000 | 68,040 | 0 | -70,000 to 0 (-100.00 %) |
Oct 06 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 9.29 | 15,000 | 139,350 | 0 | 15 K to 0 (-100.00 %) |
Oct 06 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 9.08 | 20,000 | 181,600 | 0 | 20 K to 0 (-100.00 %) |
Oct 06 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 9.02 | 35,000 | 315,700 | 0 | 35 K to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | M | 0.97 | 70,000 | 68,040 | 153,733 | |
Sep 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Buy | M | 0.97 | 70,000 | 68,040 | 0 | -70,000 to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Sell | S | 8.16 | 31,500 | 257,040 | 0 | 31.5 K to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Sell | S | 8.00 | 38,500 | 308,000 | 0 | 38.5 K to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Option Exercise | M | 0.97 | 45,260 | 43,993 | 186,848 | |
Sep 08 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Option Exercise | M | 0.40 | 4,740 | 1,891 | 0 | |
Sep 08 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Buy | M | 0.97 | 45,260 | 43,993 | 0 | -45,260 to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Buy | M | 0.40 | 4,740 | 1,891 | 0 | -4,740 to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 8.16 | 22,500 | 183,600 | 0 | 22.5 K to 0 (-100.00 %) |
Sep 08 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 8.00 | 27,500 | 220,000 | 0 | 27.5 K to 0 (-100.00 %) |
Sep 07 2010 | PLX | Protalix BioTherap ... | Palash Tzvi | Chief Operating Off ... | Option Exercise | A | 7.55 | 160,000 | 1,208,000 | 160,000 | |
Aug 09 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 4,619 | 32,333 | 763,754 | 768.4 K to 763.8 K (-0.60 %) |
Aug 09 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 48,408 | 338,856 | 768,373 | 816.8 K to 768.4 K (-5.93 %) |
Jun 23 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 52,973 | 370,811 | 816,781 | 869.8 K to 816.8 K (-6.09 %) |
May 03 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 12,691 | 88,837 | 869,754 | 882.4 K to 869.8 K (-1.44 %) |
Apr 16 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 1,309 | 9,163 | 882,445 | 883.8 K to 882.4 K (-0.15 %) |
Mar 25 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 50,000 | 350,000 | 883,754 | 933.8 K to 883.8 K (-5.35 %) |
Mar 25 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.08 | 202,700 | 1,435,116 | 933,754 | 1.1 M to 933.8 K (-17.84 %) |
Mar 25 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.02 | 127,300 | 893,646 | 1,136,454 | 1.3 M to 1.1 M (-10.07 %) |
Feb 26 2010 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | A | 6.90 | 130,000 | 897,000 | 130,000 | |
Feb 26 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Option Exercise | A | 6.90 | 145,000 | 1,000,500 | 145,000 | |
Feb 26 2010 | PLX | Protalix BioTherap ... | Aviezer David | President & CEO | Option Exercise | A | 6.90 | 250,000 | 1,725,000 | 250,000 | |
Feb 26 2010 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Option Exercise | A | 6.90 | 130,000 | 897,000 | 130,000 | |
Feb 09 2010 | PLX | Protalix BioTherap ... | Lauterbach Sandra Leigh | VP, Sales & Commerc ... | Option Exercise | A | 6.81 | 160,000 | 1,089,600 | 160,000 | |
Dec 09 2009 | PLX | Protalix BioTherap ... | Bar-Shalev Amos | Director | Buy | P | 8.20 | 680 | 5,576 | 1,680 | 1,000 to 1.7 K (+68.00 %) |
Dec 09 2009 | PLX | Protalix BioTherap ... | Bar-Shalev Amos | Director | Buy | P | 8.68 | 1,000 | 8,680 | 1,000 | 0 to 1,000 |
Nov 13 2009 | PLX | Protalix BioTherap ... | Hurvitz Eli | Director | Option Exercise | M | 0.00 | 3,384,502 | 3,385 | 0 | |
Nov 13 2009 | PLX | Protalix BioTherap ... | Hurvitz Eli | Director | Sell | J | 0.00 | 4,443,443 | 0 | 455,240 | 4.9 M to 455.2 K (-90.71 %) |
Nov 13 2009 | PLX | Protalix BioTherap ... | Hurvitz Eli | Director | Payment of Exercise | F | 11.33 | 299 | 3,388 | 4,898,683 | 4.9 M to 4.9 M (-0.01 %) |
Nov 13 2009 | PLX | Protalix BioTherap ... | Hurvitz Eli | Director | Buy | M | 0.00 | 3,384,502 | 3,385 | 4,898,982 | 1.5 M to 4.9 M (+223.48 %) |
Nov 13 2009 | PLX | Protalix BioTherap ... | Hurvitz Eli | Director | Sell | S | 10.76 | 250,000 | 2,690,000 | 1,514,480 | 1.8 M to 1.5 M (-14.17 %) |
Nov 13 2009 | PLX | Protalix BioTherap ... | Hurvitz Eli | Director | Sell | S | 10.00 | 1,121,967 | 11,219,670 | 1,764,480 | 2.9 M to 1.8 M (-38.87 %) |
Oct 21 2009 | PLX | Protalix BioTherap ... | Aviezer David | CEO and President | Option Exercise | M | 0.12 | 247,490 | 29,699 | 326,267 | |
Oct 21 2009 | PLX | Protalix BioTherap ... | Aviezer David | CEO and President | Payment of Exercise | F | 9.13 | 3,253 | 29,700 | 0 | 3.3 K to 0 (-100.00 %) |
Oct 21 2009 | PLX | Protalix BioTherap ... | Aviezer David | CEO and President | Buy | M | 0.12 | 247,490 | 29,699 | 0 | -247,490 to 0 (-100.00 %) |
Oct 21 2009 | PLX | Protalix BioTherap ... | Aviezer David | CEO and President | Sell | S | 9.36 | 34,238 | 320,468 | 0 | 34.2 K to 0 (-100.00 %) |
Oct 21 2009 | PLX | Protalix BioTherap ... | Aviezer David | CEO and President | Sell | S | 9.45 | 60,000 | 567,000 | 0 | 60 K to 0 (-100.00 %) |
Oct 21 2009 | PLX | Protalix BioTherap ... | Aviezer David | CEO and President | Sell | S | 9.43 | 150,000 | 1,414,500 | 0 | 150 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Option Exercise | M | 0.40 | 93,954 | 37,488 | 4,740 | |
Oct 19 2009 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Payment of Exercise | F | 9.48 | 3,954 | 37,484 | 0 | 4 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Buy | M | 0.40 | 93,954 | 37,488 | 0 | -93,954 to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 9.43 | 38,320 | 361,358 | 0 | 38.3 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 9.39 | 23,680 | 222,355 | 0 | 23.7 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Almon Einat Brill | VP, Product Develop ... | Sell | S | 9.39 | 28,000 | 262,920 | 0 | 28 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 9.43 | 43,120 | 406,622 | 1,263,754 | 1.3 M to 1.3 M (-3.30 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 9.39 | 25,680 | 241,135 | 1,306,874 | 1.3 M to 1.3 M (-1.93 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 9.39 | 31,200 | 292,968 | 1,332,554 | 1.4 M to 1.3 M (-2.29 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Option Exercise | M | 0.97 | 167,698 | 163,002 | 223,733 | |
Oct 19 2009 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Payment of Exercise | F | 9.21 | 17,698 | 162,999 | 0 | 17.7 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Buy | M | 0.97 | 167,698 | 163,002 | 0 | -167,698 to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Sell | S | 9.35 | 40,300 | 376,805 | 0 | 40.3 K to 0 (-100.00 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Maimon Yossi | VP, Chief Financial ... | Sell | S | 9.50 | 109,700 | 1,042,150 | 0 | 109.7 K to 0 (-100.00 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.25 | 5,000 | 36,250 | 7,788,241 | 7.8 M to 7.8 M (-0.06 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.20 | 3,581 | 25,783 | 7,793,241 | 7.8 M to 7.8 M (-0.05 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.18 | 6,419 | 46,088 | 7,796,822 | 7.8 M to 7.8 M (-0.08 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.16 | 200 | 1,432 | 7,803,241 | 7.8 M to 7.8 M (0.00 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.15 | 700 | 5,005 | 7,803,441 | 7.8 M to 7.8 M (-0.01 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.14 | 4,689 | 33,479 | 7,804,141 | 7.8 M to 7.8 M (-0.06 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.12 | 600 | 4,272 | 7,808,830 | 7.8 M to 7.8 M (-0.01 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.11 | 1,801 | 12,805 | 7,809,430 | 7.8 M to 7.8 M (-0.02 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.10 | 1,300 | 9,230 | 7,811,231 | 7.8 M to 7.8 M (-0.02 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.09 | 330 | 2,340 | 7,812,531 | 7.8 M to 7.8 M (0.00 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 7.06 | 380 | 2,683 | 7,812,861 | 7.8 M to 7.8 M (0.00 %) |
Sep 03 2009 | PLX | Protalix BioTherap ... | FROST PHILLIP MD ET AL | 10% Owner | Sell | S | 6.89 | 2,500 | 17,225 | 7,813,241 | 7.8 M to 7.8 M (-0.03 %) |